Global Neurodegenerative Disorder Therapeutics Market Research Report 2026(Status and Outlook)
The goal of therapeutic development for neurodegenerative disorders is to develop drugs that slow down or stop the neurodegenerative process. So-called neuroprotective, or disease-modifying, therapies would not only treat the symptoms but slow the continued loss of neurons in disease.
The global Neurodegenerative Disorder Therapeutics market size was estimated at USD 51200.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 7.85% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neurodegenerative Disorder Therapeutics market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurodegenerative Disorder Therapeutics market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurodegenerative Disorder Therapeutics market.
Global Neurodegenerative Disorder Therapeutics Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Biogen, Inc.
Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co., Ltd
Market Segmentation (by Type)
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
Market Segmentation (by Application)
Multiple Sclerosis
Parkinson'S Disease
Alzheimer'S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders
Geographic Segmentation
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Disorder Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurodegenerative Disorder Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Neurodegenerative Disorder Therapeutics market size was estimated at USD 51200.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 7.85% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neurodegenerative Disorder Therapeutics market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurodegenerative Disorder Therapeutics market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurodegenerative Disorder Therapeutics market.
Global Neurodegenerative Disorder Therapeutics Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Biogen, Inc.
Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co., Ltd
Market Segmentation (by Type)
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
Market Segmentation (by Application)
Multiple Sclerosis
Parkinson'S Disease
Alzheimer'S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Neurodegenerative Disorder Therapeutics Market
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Disorder Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurodegenerative Disorder Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neurodegenerative Disorder Therapeutics
1.2 Key Market Segments
1.2.1 Neurodegenerative Disorder Therapeutics Segment by Type
1.2.2 Neurodegenerative Disorder Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurodegenerative Disorder Therapeutics Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Neurodegenerative Disorder Therapeutics Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurodegenerative Disorder Therapeutics Product Life Cycle
3.3 Global Neurodegenerative Disorder Therapeutics Sales by Manufacturers (2020-2025)
3.4 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Manufacturers (2020-2025)
3.5 Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neurodegenerative Disorder Therapeutics Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neurodegenerative Disorder Therapeutics Market Competitive Situation and Trends
3.8.1 Neurodegenerative Disorder Therapeutics Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neurodegenerative Disorder Therapeutics Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISORDER THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Neurodegenerative Disorder Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurodegenerative Disorder Therapeutics Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neurodegenerative Disorder Therapeutics Market
5.7 ESG Ratings of Leading Companies
6 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2020-2025)
6.3 Global Neurodegenerative Disorder Therapeutics Market Size by Type (2020-2025)
6.4 Global Neurodegenerative Disorder Therapeutics Price by Type (2020-2025)
7 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Disorder Therapeutics Market Sales by Application (2020-2025)
7.3 Global Neurodegenerative Disorder Therapeutics Market Size (M USD) by Application (2020-2025)
7.4 Global Neurodegenerative Disorder Therapeutics Sales Growth Rate by Application (2020-2025)
8 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SALES BY REGION
8.1 Global Neurodegenerative Disorder Therapeutics Sales by Region
8.1.1 Global Neurodegenerative Disorder Therapeutics Sales by Region
8.1.2 Global Neurodegenerative Disorder Therapeutics Sales Market Share by Region
8.2 Global Neurodegenerative Disorder Therapeutics Market Size by Region
8.2.1 Global Neurodegenerative Disorder Therapeutics Market Size by Region
8.2.2 Global Neurodegenerative Disorder Therapeutics Market Size by Region
8.3 North America
8.3.1 North America Neurodegenerative Disorder Therapeutics Sales by Country
8.3.2 North America Neurodegenerative Disorder Therapeutics Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neurodegenerative Disorder Therapeutics Sales by Country
8.4.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neurodegenerative Disorder Therapeutics Sales by Region
8.5.2 Asia Pacific Neurodegenerative Disorder Therapeutics Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neurodegenerative Disorder Therapeutics Sales by Country
8.6.2 South America Neurodegenerative Disorder Therapeutics Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neurodegenerative Disorder Therapeutics Sales by Region
8.7.2 Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET PRODUCTION BY REGION
9.1 Global Production of Neurodegenerative Disorder Therapeutics by Region(2020-2025)
9.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Region (2020-2025)
9.3 Global Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neurodegenerative Disorder Therapeutics Production
9.4.1 North America Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.4.2 North America Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neurodegenerative Disorder Therapeutics Production
9.5.1 Europe Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.5.2 Europe Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neurodegenerative Disorder Therapeutics Production (2020-2025)
9.6.1 Japan Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.6.2 Japan Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neurodegenerative Disorder Therapeutics Production (2020-2025)
9.7.1 China Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.7.2 China Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Biogen, Inc.
10.1.1 Biogen, Inc. Basic Information
10.1.2 Biogen, Inc. Neurodegenerative Disorder Therapeutics Product Overview
10.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Product Market Performance
10.1.4 Biogen, Inc. Business Overview
10.1.5 Biogen, Inc. SWOT Analysis
10.1.6 Biogen, Inc. Recent Developments
10.2 Pfizer, Inc.
10.2.1 Pfizer, Inc. Basic Information
10.2.2 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product Overview
10.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product Market Performance
10.2.4 Pfizer, Inc. Business Overview
10.2.5 Pfizer, Inc. SWOT Analysis
10.2.6 Pfizer, Inc. Recent Developments
10.3 Novartis AG
10.3.1 Novartis AG Basic Information
10.3.2 Novartis AG Neurodegenerative Disorder Therapeutics Product Overview
10.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Product Market Performance
10.3.4 Novartis AG Business Overview
10.3.5 Novartis AG SWOT Analysis
10.3.6 Novartis AG Recent Developments
10.4 Sanofi S.A.
10.4.1 Sanofi S.A. Basic Information
10.4.2 Sanofi S.A. Neurodegenerative Disorder Therapeutics Product Overview
10.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Product Market Performance
10.4.4 Sanofi S.A. Business Overview
10.4.5 Sanofi S.A. Recent Developments
10.5 Teva Pharmaceutical Industries Ltd.
10.5.1 Teva Pharmaceutical Industries Ltd. Basic Information
10.5.2 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product Overview
10.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product Market Performance
10.5.4 Teva Pharmaceutical Industries Ltd. Business Overview
10.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments
10.6 UCB S.A.
10.6.1 UCB S.A. Basic Information
10.6.2 UCB S.A. Neurodegenerative Disorder Therapeutics Product Overview
10.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Product Market Performance
10.6.4 UCB S.A. Business Overview
10.6.5 UCB S.A. Recent Developments
10.7 F. Hoffmann- La Roche Ltd.
10.7.1 F. Hoffmann- La Roche Ltd. Basic Information
10.7.2 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product Overview
10.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product Market Performance
10.7.4 F. Hoffmann- La Roche Ltd. Business Overview
10.7.5 F. Hoffmann- La Roche Ltd. Recent Developments
10.8 H. Lundbeck
10.8.1 H. Lundbeck Basic Information
10.8.2 H. Lundbeck Neurodegenerative Disorder Therapeutics Product Overview
10.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Product Market Performance
10.8.4 H. Lundbeck Business Overview
10.8.5 H. Lundbeck Recent Developments
10.9 Merck KGaA
10.9.1 Merck KGaA Basic Information
10.9.2 Merck KGaA Neurodegenerative Disorder Therapeutics Product Overview
10.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Product Market Performance
10.9.4 Merck KGaA Business Overview
10.9.5 Merck KGaA Recent Developments
10.10 GlaxoSmithKline PLC
10.10.1 GlaxoSmithKline PLC Basic Information
10.10.2 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Overview
10.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Market Performance
10.10.4 GlaxoSmithKline PLC Business Overview
10.10.5 GlaxoSmithKline PLC Recent Developments
10.11 AbbVie Inc.
10.11.1 AbbVie Inc. Basic Information
10.11.2 AbbVie Inc. Neurodegenerative Disorder Therapeutics Product Overview
10.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Product Market Performance
10.11.4 AbbVie Inc. Business Overview
10.11.5 AbbVie Inc. Recent Developments
10.12 Bristol Myers Squibb Company
10.12.1 Bristol Myers Squibb Company Basic Information
10.12.2 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Overview
10.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Market Performance
10.12.4 Bristol Myers Squibb Company Business Overview
10.12.5 Bristol Myers Squibb Company Recent Developments
10.13 Boehringer Ingeiheim International GmbH
10.13.1 Boehringer Ingeiheim International GmbH Basic Information
10.13.2 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Overview
10.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Market Performance
10.13.4 Boehringer Ingeiheim International GmbH Business Overview
10.13.5 Boehringer Ingeiheim International GmbH Recent Developments
10.14 Bayer AG
10.14.1 Bayer AG Basic Information
10.14.2 Bayer AG Neurodegenerative Disorder Therapeutics Product Overview
10.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Product Market Performance
10.14.4 Bayer AG Business Overview
10.14.5 Bayer AG Recent Developments
10.15 Eisai Co., Ltd
10.15.1 Eisai Co., Ltd Basic Information
10.15.2 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product Overview
10.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product Market Performance
10.15.4 Eisai Co., Ltd Business Overview
10.15.5 Eisai Co., Ltd Recent Developments
11 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET FORECAST BY REGION
11.1 Global Neurodegenerative Disorder Therapeutics Market Size Forecast
11.2 Global Neurodegenerative Disorder Therapeutics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurodegenerative Disorder Therapeutics Market Size Forecast by Country
11.2.3 Asia Pacific Neurodegenerative Disorder Therapeutics Market Size Forecast by Region
11.2.4 South America Neurodegenerative Disorder Therapeutics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neurodegenerative Disorder Therapeutics by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Neurodegenerative Disorder Therapeutics Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Neurodegenerative Disorder Therapeutics by Type (2026-2035)
12.1.2 Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Neurodegenerative Disorder Therapeutics by Type (2026-2035)
12.2 Global Neurodegenerative Disorder Therapeutics Market Forecast by Application (2026-2035)
12.2.1 Global Neurodegenerative Disorder Therapeutics Sales (K MT) Forecast by Application
12.2.2 Global Neurodegenerative Disorder Therapeutics Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neurodegenerative Disorder Therapeutics
1.2 Key Market Segments
1.2.1 Neurodegenerative Disorder Therapeutics Segment by Type
1.2.2 Neurodegenerative Disorder Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurodegenerative Disorder Therapeutics Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Neurodegenerative Disorder Therapeutics Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurodegenerative Disorder Therapeutics Product Life Cycle
3.3 Global Neurodegenerative Disorder Therapeutics Sales by Manufacturers (2020-2025)
3.4 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Manufacturers (2020-2025)
3.5 Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neurodegenerative Disorder Therapeutics Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neurodegenerative Disorder Therapeutics Market Competitive Situation and Trends
3.8.1 Neurodegenerative Disorder Therapeutics Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neurodegenerative Disorder Therapeutics Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISORDER THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Neurodegenerative Disorder Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurodegenerative Disorder Therapeutics Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neurodegenerative Disorder Therapeutics Market
5.7 ESG Ratings of Leading Companies
6 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2020-2025)
6.3 Global Neurodegenerative Disorder Therapeutics Market Size by Type (2020-2025)
6.4 Global Neurodegenerative Disorder Therapeutics Price by Type (2020-2025)
7 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Disorder Therapeutics Market Sales by Application (2020-2025)
7.3 Global Neurodegenerative Disorder Therapeutics Market Size (M USD) by Application (2020-2025)
7.4 Global Neurodegenerative Disorder Therapeutics Sales Growth Rate by Application (2020-2025)
8 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SALES BY REGION
8.1 Global Neurodegenerative Disorder Therapeutics Sales by Region
8.1.1 Global Neurodegenerative Disorder Therapeutics Sales by Region
8.1.2 Global Neurodegenerative Disorder Therapeutics Sales Market Share by Region
8.2 Global Neurodegenerative Disorder Therapeutics Market Size by Region
8.2.1 Global Neurodegenerative Disorder Therapeutics Market Size by Region
8.2.2 Global Neurodegenerative Disorder Therapeutics Market Size by Region
8.3 North America
8.3.1 North America Neurodegenerative Disorder Therapeutics Sales by Country
8.3.2 North America Neurodegenerative Disorder Therapeutics Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neurodegenerative Disorder Therapeutics Sales by Country
8.4.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neurodegenerative Disorder Therapeutics Sales by Region
8.5.2 Asia Pacific Neurodegenerative Disorder Therapeutics Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neurodegenerative Disorder Therapeutics Sales by Country
8.6.2 South America Neurodegenerative Disorder Therapeutics Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neurodegenerative Disorder Therapeutics Sales by Region
8.7.2 Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET PRODUCTION BY REGION
9.1 Global Production of Neurodegenerative Disorder Therapeutics by Region(2020-2025)
9.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Region (2020-2025)
9.3 Global Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neurodegenerative Disorder Therapeutics Production
9.4.1 North America Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.4.2 North America Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neurodegenerative Disorder Therapeutics Production
9.5.1 Europe Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.5.2 Europe Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neurodegenerative Disorder Therapeutics Production (2020-2025)
9.6.1 Japan Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.6.2 Japan Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neurodegenerative Disorder Therapeutics Production (2020-2025)
9.7.1 China Neurodegenerative Disorder Therapeutics Production Growth Rate (2020-2025)
9.7.2 China Neurodegenerative Disorder Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Biogen, Inc.
10.1.1 Biogen, Inc. Basic Information
10.1.2 Biogen, Inc. Neurodegenerative Disorder Therapeutics Product Overview
10.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Product Market Performance
10.1.4 Biogen, Inc. Business Overview
10.1.5 Biogen, Inc. SWOT Analysis
10.1.6 Biogen, Inc. Recent Developments
10.2 Pfizer, Inc.
10.2.1 Pfizer, Inc. Basic Information
10.2.2 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product Overview
10.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product Market Performance
10.2.4 Pfizer, Inc. Business Overview
10.2.5 Pfizer, Inc. SWOT Analysis
10.2.6 Pfizer, Inc. Recent Developments
10.3 Novartis AG
10.3.1 Novartis AG Basic Information
10.3.2 Novartis AG Neurodegenerative Disorder Therapeutics Product Overview
10.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Product Market Performance
10.3.4 Novartis AG Business Overview
10.3.5 Novartis AG SWOT Analysis
10.3.6 Novartis AG Recent Developments
10.4 Sanofi S.A.
10.4.1 Sanofi S.A. Basic Information
10.4.2 Sanofi S.A. Neurodegenerative Disorder Therapeutics Product Overview
10.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Product Market Performance
10.4.4 Sanofi S.A. Business Overview
10.4.5 Sanofi S.A. Recent Developments
10.5 Teva Pharmaceutical Industries Ltd.
10.5.1 Teva Pharmaceutical Industries Ltd. Basic Information
10.5.2 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product Overview
10.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product Market Performance
10.5.4 Teva Pharmaceutical Industries Ltd. Business Overview
10.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments
10.6 UCB S.A.
10.6.1 UCB S.A. Basic Information
10.6.2 UCB S.A. Neurodegenerative Disorder Therapeutics Product Overview
10.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Product Market Performance
10.6.4 UCB S.A. Business Overview
10.6.5 UCB S.A. Recent Developments
10.7 F. Hoffmann- La Roche Ltd.
10.7.1 F. Hoffmann- La Roche Ltd. Basic Information
10.7.2 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product Overview
10.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product Market Performance
10.7.4 F. Hoffmann- La Roche Ltd. Business Overview
10.7.5 F. Hoffmann- La Roche Ltd. Recent Developments
10.8 H. Lundbeck
10.8.1 H. Lundbeck Basic Information
10.8.2 H. Lundbeck Neurodegenerative Disorder Therapeutics Product Overview
10.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Product Market Performance
10.8.4 H. Lundbeck Business Overview
10.8.5 H. Lundbeck Recent Developments
10.9 Merck KGaA
10.9.1 Merck KGaA Basic Information
10.9.2 Merck KGaA Neurodegenerative Disorder Therapeutics Product Overview
10.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Product Market Performance
10.9.4 Merck KGaA Business Overview
10.9.5 Merck KGaA Recent Developments
10.10 GlaxoSmithKline PLC
10.10.1 GlaxoSmithKline PLC Basic Information
10.10.2 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Overview
10.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Market Performance
10.10.4 GlaxoSmithKline PLC Business Overview
10.10.5 GlaxoSmithKline PLC Recent Developments
10.11 AbbVie Inc.
10.11.1 AbbVie Inc. Basic Information
10.11.2 AbbVie Inc. Neurodegenerative Disorder Therapeutics Product Overview
10.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Product Market Performance
10.11.4 AbbVie Inc. Business Overview
10.11.5 AbbVie Inc. Recent Developments
10.12 Bristol Myers Squibb Company
10.12.1 Bristol Myers Squibb Company Basic Information
10.12.2 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Overview
10.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Market Performance
10.12.4 Bristol Myers Squibb Company Business Overview
10.12.5 Bristol Myers Squibb Company Recent Developments
10.13 Boehringer Ingeiheim International GmbH
10.13.1 Boehringer Ingeiheim International GmbH Basic Information
10.13.2 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Overview
10.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Market Performance
10.13.4 Boehringer Ingeiheim International GmbH Business Overview
10.13.5 Boehringer Ingeiheim International GmbH Recent Developments
10.14 Bayer AG
10.14.1 Bayer AG Basic Information
10.14.2 Bayer AG Neurodegenerative Disorder Therapeutics Product Overview
10.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Product Market Performance
10.14.4 Bayer AG Business Overview
10.14.5 Bayer AG Recent Developments
10.15 Eisai Co., Ltd
10.15.1 Eisai Co., Ltd Basic Information
10.15.2 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product Overview
10.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product Market Performance
10.15.4 Eisai Co., Ltd Business Overview
10.15.5 Eisai Co., Ltd Recent Developments
11 NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET FORECAST BY REGION
11.1 Global Neurodegenerative Disorder Therapeutics Market Size Forecast
11.2 Global Neurodegenerative Disorder Therapeutics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurodegenerative Disorder Therapeutics Market Size Forecast by Country
11.2.3 Asia Pacific Neurodegenerative Disorder Therapeutics Market Size Forecast by Region
11.2.4 South America Neurodegenerative Disorder Therapeutics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neurodegenerative Disorder Therapeutics by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Neurodegenerative Disorder Therapeutics Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Neurodegenerative Disorder Therapeutics by Type (2026-2035)
12.1.2 Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Neurodegenerative Disorder Therapeutics by Type (2026-2035)
12.2 Global Neurodegenerative Disorder Therapeutics Market Forecast by Application (2026-2035)
12.2.1 Global Neurodegenerative Disorder Therapeutics Sales (K MT) Forecast by Application
12.2.2 Global Neurodegenerative Disorder Therapeutics Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neurodegenerative Disorder Therapeutics Market Size by Type (M USD)
Table 4. Global Neurodegenerative Disorder Therapeutics Market Size by Application
Table 5. Neurodegenerative Disorder Therapeutics Market Size Comparison by Region (M USD)
Table 6. Global Neurodegenerative Disorder Therapeutics Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Neurodegenerative Disorder Therapeutics Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Neurodegenerative Disorder Therapeutics Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2025)
Table 11. Global Market Neurodegenerative Disorder Therapeutics Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Neurodegenerative Disorder Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neurodegenerative Disorder Therapeutics Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Neurodegenerative Disorder Therapeutics Sales by Type (K MT)
Table 27. Global Neurodegenerative Disorder Therapeutics Market Size by Type (M USD)
Table 28. Global Neurodegenerative Disorder Therapeutics Sales (K MT) by Type (2020-2025)
Table 29. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2020-2025)
Table 30. Global Neurodegenerative Disorder Therapeutics Market Size (M USD) by Type (2020-2025)
Table 31. Global Neurodegenerative Disorder Therapeutics Market Share by Type (2020-2025)
Table 32. Global Neurodegenerative Disorder Therapeutics Price (USD/KG) by Type (2020-2025)
Table 33. Global Neurodegenerative Disorder Therapeutics Sales (K MT) by Application
Table 34. Global Neurodegenerative Disorder Therapeutics Market Size by Application
Table 35. Global Neurodegenerative Disorder Therapeutics Sales by Application (2020-2025) & (K MT)
Table 36. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2020-2025)
Table 37. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2020-2025) & (M USD)
Table 38. Global Neurodegenerative Disorder Therapeutics Market Share by Application (2020-2025)
Table 39. Global Neurodegenerative Disorder Therapeutics Sales Growth Rate by Application (2020-2025)
Table 40. Global Neurodegenerative Disorder Therapeutics Sales by Region (2020-2025) & (K MT)
Table 41. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Region (2020-2025)
Table 42. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (M USD)
Table 43. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025)
Table 44. North America Neurodegenerative Disorder Therapeutics Sales by Country (2020-2025) & (K MT)
Table 45. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Neurodegenerative Disorder Therapeutics Sales by Country (2020-2025) & (K MT)
Table 47. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Neurodegenerative Disorder Therapeutics Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (M USD)
Table 50. South America Neurodegenerative Disorder Therapeutics Sales by Country (2020-2025) & (K MT)
Table 51. South America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (M USD)
Table 54. Global Neurodegenerative Disorder Therapeutics Production (K MT) by Region(2020-2025)
Table 55. Global Neurodegenerative Disorder Therapeutics Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Region (2020-2025)
Table 57. Global Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Biogen, Inc. Basic Information
Table 63. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product Overview
Table 64. Biogen, Inc. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Biogen, Inc. Business Overview
Table 66. Biogen, Inc. SWOT Analysis
Table 67. Biogen, Inc. Recent Developments
Table 68. Pfizer, Inc. Basic Information
Table 69. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product Overview
Table 70. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Pfizer, Inc. Business Overview
Table 72. Pfizer, Inc. SWOT Analysis
Table 73. Pfizer, Inc. Recent Developments
Table 74. Novartis AG Basic Information
Table 75. Novartis AG Neurodegenerative Disorder Therapeutics Product Overview
Table 76. Novartis AG Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Novartis AG Business Overview
Table 78. Novartis AG SWOT Analysis
Table 79. Novartis AG Recent Developments
Table 80. Sanofi S.A. Basic Information
Table 81. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product Overview
Table 82. Sanofi S.A. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Sanofi S.A. Business Overview
Table 84. Sanofi S.A. Recent Developments
Table 85. Teva Pharmaceutical Industries Ltd. Basic Information
Table 86. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product Overview
Table 87. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Teva Pharmaceutical Industries Ltd. Business Overview
Table 89. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 90. UCB S.A. Basic Information
Table 91. UCB S.A. Neurodegenerative Disorder Therapeutics Product Overview
Table 92. UCB S.A. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. UCB S.A. Business Overview
Table 94. UCB S.A. Recent Developments
Table 95. F. Hoffmann- La Roche Ltd. Basic Information
Table 96. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product Overview
Table 97. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. F. Hoffmann- La Roche Ltd. Business Overview
Table 99. F. Hoffmann- La Roche Ltd. Recent Developments
Table 100. H. Lundbeck Basic Information
Table 101. H. Lundbeck Neurodegenerative Disorder Therapeutics Product Overview
Table 102. H. Lundbeck Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. H. Lundbeck Business Overview
Table 104. H. Lundbeck Recent Developments
Table 105. Merck KGaA Basic Information
Table 106. Merck KGaA Neurodegenerative Disorder Therapeutics Product Overview
Table 107. Merck KGaA Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Merck KGaA Business Overview
Table 109. Merck KGaA Recent Developments
Table 110. GlaxoSmithKline PLC Basic Information
Table 111. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Overview
Table 112. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. GlaxoSmithKline PLC Business Overview
Table 114. GlaxoSmithKline PLC Recent Developments
Table 115. AbbVie Inc. Basic Information
Table 116. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product Overview
Table 117. AbbVie Inc. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. AbbVie Inc. Business Overview
Table 119. AbbVie Inc. Recent Developments
Table 120. Bristol Myers Squibb Company Basic Information
Table 121. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Overview
Table 122. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Bristol Myers Squibb Company Business Overview
Table 124. Bristol Myers Squibb Company Recent Developments
Table 125. Boehringer Ingeiheim International GmbH Basic Information
Table 126. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Overview
Table 127. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. Boehringer Ingeiheim International GmbH Business Overview
Table 129. Boehringer Ingeiheim International GmbH Recent Developments
Table 130. Bayer AG Basic Information
Table 131. Bayer AG Neurodegenerative Disorder Therapeutics Product Overview
Table 132. Bayer AG Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Bayer AG Business Overview
Table 134. Bayer AG Recent Developments
Table 135. Eisai Co., Ltd Basic Information
Table 136. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product Overview
Table 137. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Eisai Co., Ltd Business Overview
Table 139. Eisai Co., Ltd Recent Developments
Table 140. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Region (2026-2035) & (K MT)
Table 141. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Region (2026-2035) & (M USD)
Table 142. North America Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (K MT)
Table 143. North America Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 144. Europe Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (K MT)
Table 145. Europe Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 146. Asia Pacific Neurodegenerative Disorder Therapeutics Sales Forecast by Region (2026-2035) & (K MT)
Table 147. Asia Pacific Neurodegenerative Disorder Therapeutics Market Size Forecast by Region (2026-2035) & (M USD)
Table 148. South America Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (K MT)
Table 149. South America Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 150. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (Units)
Table 151. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Type (2026-2035) & (K MT)
Table 153. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Type (2026-2035) & (M USD)
Table 154. Global Neurodegenerative Disorder Therapeutics Price Forecast by Type (2026-2035) & (USD/KG)
Table 155. Global Neurodegenerative Disorder Therapeutics Sales (K MT) Forecast by Application (2026-2035)
Table 156. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neurodegenerative Disorder Therapeutics Market Size by Type (M USD)
Table 4. Global Neurodegenerative Disorder Therapeutics Market Size by Application
Table 5. Neurodegenerative Disorder Therapeutics Market Size Comparison by Region (M USD)
Table 6. Global Neurodegenerative Disorder Therapeutics Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Neurodegenerative Disorder Therapeutics Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Neurodegenerative Disorder Therapeutics Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2025)
Table 11. Global Market Neurodegenerative Disorder Therapeutics Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Neurodegenerative Disorder Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neurodegenerative Disorder Therapeutics Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Neurodegenerative Disorder Therapeutics Sales by Type (K MT)
Table 27. Global Neurodegenerative Disorder Therapeutics Market Size by Type (M USD)
Table 28. Global Neurodegenerative Disorder Therapeutics Sales (K MT) by Type (2020-2025)
Table 29. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2020-2025)
Table 30. Global Neurodegenerative Disorder Therapeutics Market Size (M USD) by Type (2020-2025)
Table 31. Global Neurodegenerative Disorder Therapeutics Market Share by Type (2020-2025)
Table 32. Global Neurodegenerative Disorder Therapeutics Price (USD/KG) by Type (2020-2025)
Table 33. Global Neurodegenerative Disorder Therapeutics Sales (K MT) by Application
Table 34. Global Neurodegenerative Disorder Therapeutics Market Size by Application
Table 35. Global Neurodegenerative Disorder Therapeutics Sales by Application (2020-2025) & (K MT)
Table 36. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2020-2025)
Table 37. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2020-2025) & (M USD)
Table 38. Global Neurodegenerative Disorder Therapeutics Market Share by Application (2020-2025)
Table 39. Global Neurodegenerative Disorder Therapeutics Sales Growth Rate by Application (2020-2025)
Table 40. Global Neurodegenerative Disorder Therapeutics Sales by Region (2020-2025) & (K MT)
Table 41. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Region (2020-2025)
Table 42. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (M USD)
Table 43. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025)
Table 44. North America Neurodegenerative Disorder Therapeutics Sales by Country (2020-2025) & (K MT)
Table 45. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Neurodegenerative Disorder Therapeutics Sales by Country (2020-2025) & (K MT)
Table 47. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Neurodegenerative Disorder Therapeutics Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (M USD)
Table 50. South America Neurodegenerative Disorder Therapeutics Sales by Country (2020-2025) & (K MT)
Table 51. South America Neurodegenerative Disorder Therapeutics Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025) & (M USD)
Table 54. Global Neurodegenerative Disorder Therapeutics Production (K MT) by Region(2020-2025)
Table 55. Global Neurodegenerative Disorder Therapeutics Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Region (2020-2025)
Table 57. Global Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Neurodegenerative Disorder Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Biogen, Inc. Basic Information
Table 63. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product Overview
Table 64. Biogen, Inc. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Biogen, Inc. Business Overview
Table 66. Biogen, Inc. SWOT Analysis
Table 67. Biogen, Inc. Recent Developments
Table 68. Pfizer, Inc. Basic Information
Table 69. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product Overview
Table 70. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Pfizer, Inc. Business Overview
Table 72. Pfizer, Inc. SWOT Analysis
Table 73. Pfizer, Inc. Recent Developments
Table 74. Novartis AG Basic Information
Table 75. Novartis AG Neurodegenerative Disorder Therapeutics Product Overview
Table 76. Novartis AG Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Novartis AG Business Overview
Table 78. Novartis AG SWOT Analysis
Table 79. Novartis AG Recent Developments
Table 80. Sanofi S.A. Basic Information
Table 81. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product Overview
Table 82. Sanofi S.A. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Sanofi S.A. Business Overview
Table 84. Sanofi S.A. Recent Developments
Table 85. Teva Pharmaceutical Industries Ltd. Basic Information
Table 86. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product Overview
Table 87. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Teva Pharmaceutical Industries Ltd. Business Overview
Table 89. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 90. UCB S.A. Basic Information
Table 91. UCB S.A. Neurodegenerative Disorder Therapeutics Product Overview
Table 92. UCB S.A. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. UCB S.A. Business Overview
Table 94. UCB S.A. Recent Developments
Table 95. F. Hoffmann- La Roche Ltd. Basic Information
Table 96. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product Overview
Table 97. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. F. Hoffmann- La Roche Ltd. Business Overview
Table 99. F. Hoffmann- La Roche Ltd. Recent Developments
Table 100. H. Lundbeck Basic Information
Table 101. H. Lundbeck Neurodegenerative Disorder Therapeutics Product Overview
Table 102. H. Lundbeck Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. H. Lundbeck Business Overview
Table 104. H. Lundbeck Recent Developments
Table 105. Merck KGaA Basic Information
Table 106. Merck KGaA Neurodegenerative Disorder Therapeutics Product Overview
Table 107. Merck KGaA Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Merck KGaA Business Overview
Table 109. Merck KGaA Recent Developments
Table 110. GlaxoSmithKline PLC Basic Information
Table 111. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Overview
Table 112. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. GlaxoSmithKline PLC Business Overview
Table 114. GlaxoSmithKline PLC Recent Developments
Table 115. AbbVie Inc. Basic Information
Table 116. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product Overview
Table 117. AbbVie Inc. Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. AbbVie Inc. Business Overview
Table 119. AbbVie Inc. Recent Developments
Table 120. Bristol Myers Squibb Company Basic Information
Table 121. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Overview
Table 122. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Bristol Myers Squibb Company Business Overview
Table 124. Bristol Myers Squibb Company Recent Developments
Table 125. Boehringer Ingeiheim International GmbH Basic Information
Table 126. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Overview
Table 127. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. Boehringer Ingeiheim International GmbH Business Overview
Table 129. Boehringer Ingeiheim International GmbH Recent Developments
Table 130. Bayer AG Basic Information
Table 131. Bayer AG Neurodegenerative Disorder Therapeutics Product Overview
Table 132. Bayer AG Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Bayer AG Business Overview
Table 134. Bayer AG Recent Developments
Table 135. Eisai Co., Ltd Basic Information
Table 136. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product Overview
Table 137. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Eisai Co., Ltd Business Overview
Table 139. Eisai Co., Ltd Recent Developments
Table 140. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Region (2026-2035) & (K MT)
Table 141. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Region (2026-2035) & (M USD)
Table 142. North America Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (K MT)
Table 143. North America Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 144. Europe Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (K MT)
Table 145. Europe Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 146. Asia Pacific Neurodegenerative Disorder Therapeutics Sales Forecast by Region (2026-2035) & (K MT)
Table 147. Asia Pacific Neurodegenerative Disorder Therapeutics Market Size Forecast by Region (2026-2035) & (M USD)
Table 148. South America Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (K MT)
Table 149. South America Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 150. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales Forecast by Country (2026-2035) & (Units)
Table 151. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Type (2026-2035) & (K MT)
Table 153. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Type (2026-2035) & (M USD)
Table 154. Global Neurodegenerative Disorder Therapeutics Price Forecast by Type (2026-2035) & (USD/KG)
Table 155. Global Neurodegenerative Disorder Therapeutics Sales (K MT) Forecast by Application (2026-2035)
Table 156. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neurodegenerative Disorder Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Disorder Therapeutics Market Size (M USD), 2025-2035
Figure 5. Global Neurodegenerative Disorder Therapeutics Market Size (M USD) (2020-2035)
Figure 6. Global Neurodegenerative Disorder Therapeutics Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurodegenerative Disorder Therapeutics Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neurodegenerative Disorder Therapeutics Product Life Cycle
Figure 13. Neurodegenerative Disorder Therapeutics Sales Share by Manufacturers in 2025
Figure 14. Global Neurodegenerative Disorder Therapeutics Revenue Share by Manufacturers in 2025
Figure 15. Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Neurodegenerative Disorder Therapeutics Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2025
Figure 18. Industry Chain Map of Neurodegenerative Disorder Therapeutics
Figure 19. Global Neurodegenerative Disorder Therapeutics Market PEST Analysis
Figure 20. Global Neurodegenerative Disorder Therapeutics Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neurodegenerative Disorder Therapeutics Market Share by Type
Figure 27. Sales Market Share of Neurodegenerative Disorder Therapeutics by Type (2020-2025)
Figure 28. Sales Market Share of Neurodegenerative Disorder Therapeutics by Type in 2025
Figure 29. Market Share of Neurodegenerative Disorder Therapeutics by Type (2020-2025)
Figure 30. Market Share of Neurodegenerative Disorder Therapeutics by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neurodegenerative Disorder Therapeutics Market Share by Application
Figure 33. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2020-2025)
Figure 34. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Application in 2025
Figure 35. Global Neurodegenerative Disorder Therapeutics Market Share by Application (2020-2025)
Figure 36. Global Neurodegenerative Disorder Therapeutics Market Share by Application in 2025
Figure 37. Global Neurodegenerative Disorder Therapeutics Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Region (2020-2025)
Figure 39. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025)
Figure 40. North America Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neurodegenerative Disorder Therapeutics Sales Market Share by Country in 2024
Figure 43. North America Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neurodegenerative Disorder Therapeutics Market Size by Country in 2024
Figure 45. U.S. Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neurodegenerative Disorder Therapeutics Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neurodegenerative Disorder Therapeutics Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neurodegenerative Disorder Therapeutics Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neurodegenerative Disorder Therapeutics Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neurodegenerative Disorder Therapeutics Sales Market Share by Country in 2024
Figure 53. Europe Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neurodegenerative Disorder Therapeutics Market Size by Country in 2024
Figure 55. Germany Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neurodegenerative Disorder Therapeutics Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neurodegenerative Disorder Therapeutics Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neurodegenerative Disorder Therapeutics Market Size by Region in 2024
Figure 68. China Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neurodegenerative Disorder Therapeutics Sales and Growth Rate (K MT)
Figure 79. South America Neurodegenerative Disorder Therapeutics Sales Market Share by Country in 2024
Figure 80. South America Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (M USD)
Figure 81. South America Neurodegenerative Disorder Therapeutics Market Size by Country in 2024
Figure 82. Brazil Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size by Region in 2024
Figure 92. Saudi Arabia Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neurodegenerative Disorder Therapeutics Production Market Share by Region (2020-2025)
Figure 103. North America Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Neurodegenerative Disorder Therapeutics Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Neurodegenerative Disorder Therapeutics Market Share Forecast by Type (2026-2035)
Figure 111. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Application (2026-2035)
Figure 112. Global Neurodegenerative Disorder Therapeutics Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Neurodegenerative Disorder Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Disorder Therapeutics Market Size (M USD), 2025-2035
Figure 5. Global Neurodegenerative Disorder Therapeutics Market Size (M USD) (2020-2035)
Figure 6. Global Neurodegenerative Disorder Therapeutics Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurodegenerative Disorder Therapeutics Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neurodegenerative Disorder Therapeutics Product Life Cycle
Figure 13. Neurodegenerative Disorder Therapeutics Sales Share by Manufacturers in 2025
Figure 14. Global Neurodegenerative Disorder Therapeutics Revenue Share by Manufacturers in 2025
Figure 15. Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Neurodegenerative Disorder Therapeutics Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2025
Figure 18. Industry Chain Map of Neurodegenerative Disorder Therapeutics
Figure 19. Global Neurodegenerative Disorder Therapeutics Market PEST Analysis
Figure 20. Global Neurodegenerative Disorder Therapeutics Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neurodegenerative Disorder Therapeutics Market Share by Type
Figure 27. Sales Market Share of Neurodegenerative Disorder Therapeutics by Type (2020-2025)
Figure 28. Sales Market Share of Neurodegenerative Disorder Therapeutics by Type in 2025
Figure 29. Market Share of Neurodegenerative Disorder Therapeutics by Type (2020-2025)
Figure 30. Market Share of Neurodegenerative Disorder Therapeutics by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neurodegenerative Disorder Therapeutics Market Share by Application
Figure 33. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2020-2025)
Figure 34. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Application in 2025
Figure 35. Global Neurodegenerative Disorder Therapeutics Market Share by Application (2020-2025)
Figure 36. Global Neurodegenerative Disorder Therapeutics Market Share by Application in 2025
Figure 37. Global Neurodegenerative Disorder Therapeutics Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neurodegenerative Disorder Therapeutics Sales Market Share by Region (2020-2025)
Figure 39. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2020-2025)
Figure 40. North America Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neurodegenerative Disorder Therapeutics Sales Market Share by Country in 2024
Figure 43. North America Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neurodegenerative Disorder Therapeutics Market Size by Country in 2024
Figure 45. U.S. Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neurodegenerative Disorder Therapeutics Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neurodegenerative Disorder Therapeutics Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neurodegenerative Disorder Therapeutics Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neurodegenerative Disorder Therapeutics Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neurodegenerative Disorder Therapeutics Sales Market Share by Country in 2024
Figure 53. Europe Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neurodegenerative Disorder Therapeutics Market Size by Country in 2024
Figure 55. Germany Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neurodegenerative Disorder Therapeutics Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neurodegenerative Disorder Therapeutics Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neurodegenerative Disorder Therapeutics Market Size by Region in 2024
Figure 68. China Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neurodegenerative Disorder Therapeutics Sales and Growth Rate (K MT)
Figure 79. South America Neurodegenerative Disorder Therapeutics Sales Market Share by Country in 2024
Figure 80. South America Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (M USD)
Figure 81. South America Neurodegenerative Disorder Therapeutics Market Size by Country in 2024
Figure 82. Brazil Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size by Region in 2024
Figure 92. Saudi Arabia Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neurodegenerative Disorder Therapeutics Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neurodegenerative Disorder Therapeutics Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neurodegenerative Disorder Therapeutics Production Market Share by Region (2020-2025)
Figure 103. North America Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neurodegenerative Disorder Therapeutics Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Neurodegenerative Disorder Therapeutics Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Neurodegenerative Disorder Therapeutics Market Share Forecast by Type (2026-2035)
Figure 111. Global Neurodegenerative Disorder Therapeutics Sales Forecast by Application (2026-2035)
Figure 112. Global Neurodegenerative Disorder Therapeutics Market Share Forecast by Application (2026-2035)
